Rain oncology stock.

Rain Therapeutics (RAIN) LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Rain Therapeutics today and set a price target of $17.00 . The company’s shares closed last Thursday at $9.28.Web

Rain oncology stock. Things To Know About Rain oncology stock.

Nov 22, 2023 · Which Rain Oncology insiders have been buying company stock? The following insiders have purchased RAIN shares in the last 24 months: Aaron I Davis ($5,667,995.96), Bvf Partners L P/Il ($9,971,387.14), Franklin M Berger ($351,000.00), and Kevin C Tang ($1,179,304.12). Track Rain Therapeutics Inc (RAIN) Stock Price, Quote, latest community messages, chart, news and other stock related information.Stock analysis for Rain Oncology Inc (RAIN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.WebNov 04, 2022. NEWARK, Calif., November 4, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting …WebThe oncology industry is expected to grow considerably in 2022, driven by the rising occurrence of cancer in the U.S. population. Furthermore, increasing investments by biopharmaceutical companies and the government should fuel the industry's growth. Given the industry's bright growth prospects, Wall Street analysts expect the stocks of …

Rain Oncology. stock last closed at $1.11, up 5.71% from the previous day, and has decreased 86.09% in one year. It has underperformed other stocks in the Biotechnology industry by 0.59 percentage points. Rain Oncology stock is currently +35.37% from its 52-week low of $0.82, and -92.33% from its 52-week high of $14.48.At …WebWhat is Rain Oncology's stock price target for 2024? 12 Wall Street research analysts have issued twelve-month price objectives for Rain Oncology's shares. Their RAIN share price targets range from $11.00 to $24.00. On average, they anticipate the company's stock price to reach $17.00 in the next year.NEWARK, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology... – Quarter-end cash position of $123.2 million provides ample cash runway into first half of 2024 – – Phase 3 MANTRA topline data expected earlier than...

Jun 15, 2023 · Rain Oncology has a market capitalisation of US$46m and burnt through US$68m last year, which is 147% of the company's market value. That suggests the company may have some funding difficulties ... Rain Oncology Inc (RAIN) stock is down -87.44% while the S&P 500 has risen 0.1% as of 11:09 AM on Monday, May 22. RAIN is down -$8.68 from the previous closing price of $9.93 on volume of 16,197,454 shares. Over the past year the S&P 500 is higher by 5.60% while RAIN is down -51.92%. RAIN lost -$2.61 per share in the over the last 12 months.

[relinking] Home History Owners Mission How It Works How It Makes Money A Brief History of Rain Therapeutics Inc. (RAIN) Rain Therapeutics Inc. is a biotechnology company focused on targeted therapies for patients with cancer. The company was founded in 2017 and is headquartered in Newark, California. Since its inception, Rain Therapeutics has …Shares of RAIN stock opened at $1.11 on Friday. Rain Oncology has a 12-month low of $0.82 and a 12-month high of $14.48. The firm has a fifty day moving average of $1.02 and a 200-day moving ...1 Jun 2021 ... Rain Therapeutics (RAIN) is a clinical-stage precision oncology company. They recently went public in 2021. Co-founder and CEO, Avanish ...Stock Quote & Chart. Historical Price Lookup. ... Rain Oncology Announces Collaborator Poster Presentation at the American Association for Cancer Research (AACR ...

9 Mar 2023 ... shares of the Company's convertible preferred stock converted into 7,341,860 shares of Common Stock. ... assets or voting stock of Rain Oncology ...

Stock Price Forecast. The 4 analysts offering 12-month price forecasts for Rain Oncology Inc have a median target of 1.38, with a high estimate of 2.00 and a low estimate of 1.00. The median ...

Dec 29, 2022 · Rain Therapeutics. NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology ... Rain and other forms of precipitation fall from the clouds. When warm air passes over a body of water, it causes the water to evaporate. Once the water rises high enough, it clumps with other water vapor and becomes a cloud.Rain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for patients suffering from cancer. The company was founded by Avanish Vellanki and Robert Doebele in April 2017 and is headquartered in Newark, CA. The average price target is $1.33 with a high forecast of $2.00 and a low forecast of $1.00. The average price target represents a 20.91% change from the last ...Stock Quote & Chart. Historical Price Lookup. ... Rain Oncology Announces Collaborator Poster Presentation at the American Association for Cancer Research (AACR ...NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the ...Rain Oncology Inc (RAIN) stock is trading at $7.36 as of 1:33 PM on Tuesday, Apr 18, a loss of -$0.08, or -1.08% from the previous closing price of $7.44. The stock has traded between $7.20 and $7.45 so far today. Volume today is less active than usual.

1.05. +0.03. +2.94%. Get Rain Oncology Inc (RAIN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.1.05. +0.03. +2.94%. Get Rain Oncology Inc (RAIN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Nanopore design. The concept of nanopore sequencing emerged in the 1980s and was realized through a series of technical advances in both the nanopore and the associated motor protein 1,4,5,6,7,8 ...Which Rain Oncology insiders have been selling company stock? The following insider sold RAIN shares in the last 24 months: Boxer Capital, Llc ($1,243,750.00). How much insider selling is happening at Rain Oncology?Mar 9, 2023 · Non-cash stock-based compensation expense included in G&A expenses were approximately $0.3 million and $1.1 million for the three months and year ended December 31, 2022, respectively, as compared ... Browse 4,001 authentic oncologist stock photos, high-res images, and pictures, or explore additional oncology or oncologist and patient stock images to find the right photo at the right size and resolution for your project. oncology. oncologist and patient. doctor.Stocks / Pharmaceuticals & Biotech RAIN Rain Oncology NasdaqGS:RAIN Stock Report Add to watchlist Add to portfolio Last Price US$1.07 Market Cap …

Oct 16, 2023 · NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of ... NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC …

Nov 9, 2023 · As of November 3, 2023, Rain had approximately 36.4 million shares of common stock outstanding. About Rain Oncology Inc. Rain Oncology Inc. is a precision oncology company developing therapies ... Company Overview. Rain Oncology is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than ...WebStocks / Pharmaceuticals & Biotech RAIN Rain Oncology NasdaqGS:RAIN Stock Report Add to watchlist Add to portfolio Last Price US$1.07 Market Cap …Employment: Rain Oncology. Leadership: Rain Oncology. Stock and Other Ownership Interests: Rain Oncology. Consulting or Advisory Role: GreenPeptide, AstraZeneca, Roche/Genentech, Rain Oncology, Blueprint Medicines, Guardant Health. Patents, Royalties, Other Intellectual Property: Licensing fees for patent from Rain …WebTrack Rain Therapeutics Inc (RAIN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsMay 22, 2023 · Rain Oncology ( NASDAQ: RAIN) fell ~81% in the pre-market Monday after announcing that its lead product candidate, milademetan, did not reach the primary endpoint in a Phase 3 trial for patients ...

Description. Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology.Web

Nov 24, 2023 · RAIN News Today | Why did Rain Oncology stock go up today? S&P 500 4,559.34. DOW 35,390.15. QQQ 389.51. 12 crew members are missing, 1 dead after a cargo ship sinks off a Greek island in stormy seas. [Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad) Turned down for a loan, business owners look to family and even ...

PFS (Primary): Approximately 105 events by blinded central review to trigger primary analysis. OS, ORR, DCR, DOR. Safety. TP53. Overview. MDM2 gene CN of ≥8. Patients enrolled based on local NGS for CN, centrally confirmed by Rain's diagnostic partner, Tempus. Evaluable tumor types included: lung, breast, biliary, pancreatic and other select ...16 Oct 2023 ... Rain Oncology, Inc. ... Rain's Board of Directors and management team regularly review opportunities to generate stockholder value and are ...Rain Oncology Inc. executives and directors allegedly misled investors about the company’s progress developing a cancer drug, milademetan, resulting in a stock drop when a clinical trial revealed that the drug was ineffective, a shareholder derivative suit says. The treatment for dedifferentiated liposarcoma—a rare and aggressive cancer of the fatty …Stockholder / Stock options: Rain Therapeutics; Advisory / Consultancy: Chair of Scientific Advisory. Board for Rain Therapeutics; Honoraria (self): Guardant ...Insiders who bought Rain Oncology Inc. (NASDAQ:RAIN) stock in the last 12 months were richly rewarded last week. The company's market value increased by US$54m as a result of the stock's 21% gain ...NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate ...31 Jan 2023 ... Roth Capital Partners renewed coverage of Rain Oncology (Rain Oncology Stock Quote, Charts, News, Analysts, Financials NASDAQ:RAIN) on ...Rain Oncology Inc. Watch list NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 7:58 p.m. EST Delayed quote $ 1.1100 0.00 0.00% After Hours Volume: 1.31K Advanced Charting...Which Rain Oncology insiders have been selling company stock? The following insider sold RAIN shares in the last 24 months: Boxer Capital, Llc ($1,243,750.00). How much insider selling is happening at Rain Oncology?Rain Oncology Inc (NASDAQ: RAIN) announced topline Phase 3 MANTRA data of milademetan in patients with dedifferentiated (DD) liposarcoma (LPS). The study did not meet its primary endpoint of ...NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate ...Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences. NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a ...

Dec 29, 2022. NEWARK, Calif., December 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will change its name to Rain Oncology ... Y-mAbs Therapeutics, Inc. (Y-mAbs), is a state-of-the-art, late-stage clinical, global biopharmaceutical company that is focused on the research and development of innovative antibody-based products under investigation using a range of cutting-edge technologies, licensed from one of the largest and most prestigious cancer-care …Nov 4, 2022 · NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the ... Rain Oncology is latest troubled biotech to receive acquisition offer from Concentra. By James Waldron Oct 16, 2023 10:20am. mergers and acquisitions Tang Capital Partners Deals. Five months after ...Instagram:https://instagram. influencer investorsfinancial planner pittsburgh pacandlestick graph stocksspr stocks What is the target price for Rain Oncology (RAIN) stock? The latest price target for Rain Oncology ( NASDAQ: RAIN) was reported by Citigroup on Monday, September 18, 2023. The analyst firm set a ...Oct 13, 2023 · Rain Oncology ( NASDAQ: RAIN) has received an acquisition proposal from Concentra Biosciences, an affiliate of Tang Capital Partners, for $1.25/share in cash. The clinical-stage micro-cap cancer ... trading futures for beginnersspy vs spx Nov 04, 2022. NEWARK, Calif., November 4, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting …WebRain Oncology Inc. Class Action: RAIN Investors Should Contact Robbins LLP if They Suffered Financial Losses in Excess of $100,000. SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds ... ttoo short interest May 22, 2023 · Shares of Rain Oncology ( RAIN 0.96%) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated ... Try our powerful stock tools to help compare investments and get ideas. View Our Research Providers. Find out about our industry leading research providers. ... Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023;